At a glance
Founded in 1999 by a four-member team around founder Alexandre Fraichard, genOway now has risen to become a leader in the field of customized, genetically modified (GM) mouse, rat, and cell model creation.
Having grown to an international, multicultural team of slightly more than 100 employees* spanning 17 nationalities, we have built up our capacity to produce almost 300 GM models per year, while serving clients in:
- 28 countries in 5 continents
- 380 academic institutions and 13 EU framework projects
- 170 Life Sciences companies, including 17 of the Top 20 pharma
Activity
genOway's activities focus on customized mouse, rat, and cell line genetical modifications by combining technologies routinely used in genome engineering (Knockout, conditional Knockout, Knockin, humanization, point mutations, overexpression, etc.) with a range of innovative technological solutions to create a new generation of models of higher physiological relevancy.
Our broad technology platform enables the design and creation of models for research, target validation, drug screening, efficacy, and safety testing. The value of the scientific data obtained from these models is proportional to the quality of the model design. Thus, the generation of the right research or preclinical model requires a thorough analysis of the target gene biology paired with a clear assessment of the technical parameters.
genOway’s hallmark is indeed the scientific input provided at project start, with a project feasibility evaluation performed to define the design that best answers our customers' needs. We are the only company to invest heavily in this consulting activity, and each project feasibility analysis represents seven days of full-time equivalent activity of experts in bioinformatics, gene targeting, molecular biology, and cell biology.